Daratumumab Monotherapy Shows Benefit vs Active Monitoring for Patients With High-Risk Smoldering Multiple Myeloma
Daratumumab monotherapy demonstrated benefit versus active monitoring among patients with high-risk smoldering multiple myeloma (MM), according to phase 3 data from the Aquila study presented by Meletios-Athanasios Dimopoulos, MD, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.
Dr Dimopoulos presented these results at the 66th ASH Annual Meeting in San Diego, California.
“Daratumumab monotherapy was well-tolerated and demonstrated a clinically meaningful and significant benefit in preventing or delaying progression to active MM compared with active monitoring in patients with high-risk smoldering multiple myeloma,” wrote Dr Dimopoulous and colleagues.
“These results strongly support the benefit of early intervention with daratumumab monotherapy versus active monitoring, the current standard of care, in patients with high-risk SMM,” they added."
Source:
Dimopoulos MA, Voorhees P, Schjesvold F, et al. Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study. Presented at the 66th ASH Annual Meeting & Exposition; December 7, 2024; San Diego, California. Abstract 773.
